Recently, an article titled "Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity" was published online in Scientific Reports, a Nature journal. The study indicates that the molecular design of BGM0504 from Borui Pharmaceuticals is superior, with its agonistic activity at GLP-1R/GIPR being three times that of Tirzepatide.
This is an AI and computer simulation-based molecular optimization design. Through molecular dynamics simulations, key salt bridges in the parent peptide molecule that are invisible under electron microscopy were discovered and the positions of the side chains were specifically optimized. Ultimately, new peptide agonist BGM0504 was subjected to corresponding in vitro and in vivo experiments, proving that BGM0504 has superior efficacy compared to Tirzepatide.
Optimization Design
As one of the four major SCI journals, Nature is alongside Science, Cell, and the Proceedings of the National Academy of Sciences (PNAS), enjoying a high reputation in the academic community and serving as a barometer in the field of scientific research.
As a journal under Nature, Scientific Reports is currently published and distributed online by the Nature-Springer publishing group as an OA (Open Access) journal, mainly featuring original research results in natural science and clinical science. The editorial board of Scientific Reports chose to publish the BGM0504 study, affirming the advantages of the molecular design of Borui Pharmaceuticals' BGM0504.
Researchers explored the potential GLP-1R/GIPR agonistic activity of the Tirzepatide parent peptide through molecular dynamics and found that the key K20 residue contributes significantly to the agonistic activity of GLP-1R/GIPR. Based on these findings, researchers optimized the clinical candidate compound BGM0504 with superior agonistic activity and in vivo blood glucose-lowering and weight-reducing effects by using a new fatty acid side chain modification strategy.
In in vitro and in vivo experimental studies, it was found that in terms of GLP-1R/GIPR agonistic activity, BGM0504 is three times that of Tirzepatide, which explains why BGM0504 has a better effect on blood glucose reduction and weight loss in mice.
Furthermore, BGM0504 has a stronger binding ability to human serum albumin compared to Tirzepatide. In key pharmacokinetic studies in rats and crab-eating monkeys, the experimental animals showed good tolerance at different doses of BGM0504, and the half-life of BGM0504 can support a once-a-week dosing regimen, while maintaining a continuously high blood drug concentration and drug exposure to sustain the effect of the drug.
These studies indicate that BGM0504, as a peptide drug for the treatment of diabetes and obesity, has good safety and efficacy.

Fig.1 Structural Analysis Comparison and Optimization Strategy of Tirzepatide and BGM0504/Image Source: Borui Pharmaceuticals
Continuous Advancement
BGM0504 injection, independently developed by Borui Pharmaceuticals, is a dual agonist of GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) receptors. It can activate the downstream pathways of GIP and GLP-1, producing biological effects such as blood glucose control, weight reduction, and treatment of non-alcoholic steatohepatitis (NASH), demonstrating the potential for treating various metabolic diseases.
Information from the National Medical Products Administration's Center for Drug Evaluation shows that BGM0504 is currently undergoing trials, including a phase II clinical trial (CTR20233198) for the treatment of overweight and obesity in China; and a phase IIa clinical trial (CTR20232464) for the treatment of type 2 diabetes in China.
Completed experiments include a phase Ia clinical trial (CTR20230120) for the treatment of overweight or obesity/ type 2 diabetes in China. In the completed Ia phase clinical trial, under a dose of 2.5-15 mg, after 1 to 2 administrations, the average weight of healthy volunteers decreased by 3.24% to 8.30% compared to the baseline.
Preliminary results from a phase II clinical study of BGM0504 injection in type 2 diabetes patients under blind conditions showed that subjects in the 5mg, 10mg, and 15mg dose groups of BGM0504 injection had good tolerability and safety after dose titration for 2 to 6 weeks and target dose administration for 12 weeks; the levels of HbA1c, fasting blood glucose, and 2-hour postprandial blood glucose in subjects of all dose groups significantly decreased compared to the baseline.
Preliminary results from a phase II clinical study of BGM0504 injection in overweight/obese patients under blind conditions showed that subjects in the 5mg, 10mg, and 15mg dose groups of BGM0504 injection had good tolerability and safety after dose titration for 2 to 6 weeks and target dose administration for 12 or 24 weeks; the weight of subjects in all dose groups significantly decreased compared to the baseline.
In early July, the national researcher meeting for "Phase III Clinical Trial of BGM0504 Injection for Weight Control" was successfully held in Beijing. Professor Ji Linong, a leading figure in endocrinology at Peking Union Medical College Hospital, said that BGM0504 injection, as a new and unique dual-target mechanism, is expected to provide more comprehensive and effective treatment options for patients with diabetes and obesity.
In Conclusion
Dr. Yuan Jiandong, the first author of this paper, said: "I am very pleased to see the phased results of the BGM0504 research published in the authoritative academic journal Nature's sub-journal, gaining recognition from the international academic community. I also thank the research team for their continued hard work."
He also said that we will continue to promote the clinical development process of BGM0504. With the important breakthrough in the development of GLP-1 and GIP dual-target drugs, the encouraging safety and efficacy will enable this innovative blood glucose-lowering and weight-reducing drug to benefit more patients with diabetes and obesity in the future.
Dr. Yuan Jiandong is also the chairman of Borui Pharmaceuticals and the dean of the Drug Research Institute. He has led the development of several patented technologies of Borui Pharmaceuticals, among which the "Synthesis Method of Antiviral Nucleoside Analogs" won the "China Patent Award".
Reference:
Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity.Sci Rep 14,16680(2024).